No provisions in USMCA to change U.S. pharmaceutical patent laws: Lighthizer

(Reuters) – The United States-Mexico-Canada Agreement has no provisions that would force changes to U.S. laws with respect to pharmaceutical companies, U.S. Trade Representative Robert Lighthizer said on Tuesday.

“To the extent that a member (of Congress) thinks anything in here will stop you from changing laws, then we have to correct that,” Lighthizer said at a hearing of the Senate Finance Committee.

Reporting by Chris Prentice; Editing by Susan Thomas

Our Standards:The Thomson Reuters Trust Principles.

Visit the Source Site

Powered by WPeMatico